Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals.
The team hope the compound –developed after 10 years of painstaking research will be trialled on humans within three to four years.
The drug- which works by targeting Mycobacterium tuberculosis’ defences rather than the bacteria itself – can also take out its increasingly commonly antibiotic resistant strains.
The research funded by the Medical Research Council – is published today in the Journal of Medicinal Chemistry.
Although a vaccine for TB was developed 100 years ago, one in three people across the world are thought to be infected with the infectious disease.
About 1.7 million die from the bug each year worldwide and 7.3 million people were diagnosed and treated in 2018, up from the 6.3 million in 2016.
It is most common in Africa, India and China, but on the rise in the UK with London often described as the TB capital of Europe.
Patients are forced to take a cocktail of strong antibiotics over 6 to 8 months, often enduring unpleasant side effects with a 20% risk that the disease will return.
But now The University of Manchester team’s discovery has been proven effective in guinea pigs at Rutgers University in the United States.
The animals with acute and chronic TB infection were treated with the compound, which was discovered after investigating dozens of other derivatives and compounds thought to have similar properties.
Professor Lydia Tabernero is the project leader. She said: “The fact that the animal studies showed our compound, which doesn’t kill the bacteria directly, resulted in a significant reduction in the bacterial burden is remarkable.
“For more than 60 years, the only weapon doctors have been able to use against TB is antibiotics. But resistance is becoming an increasingly worrying problem and the prolonged treatment is difficult and distressing for patients.
“And with current treatments, there’s no guarantee the disease will be eliminated: antibiotics do not clear the infection and the risk of being infected with drug-resistant bacteria is very high.
“But by disabling this clandestine bacteria’s defences we’re thrilled to find a way that enhances the chances of the body’s immune system to do its job, and thus eliminate the pathogen.”
Mycobacterium Tuberculosis secretes molecules called Virulence Factors – the cell’s secret weapon -which block out the immune response to the infection, making it difficult to treat.
The team identified one Virulence Factor called MptpB as a suitable target, which when blocked allows white blood cells to kill Mycobacterium Tuberculosis in a more efficient way
Professor Tabernero added: “The great thing about MptpB is that there’s nothing similar in humans – so our compound which blocks it is not toxic to the human cells.
“Because the bacteria hasn’t been threatened directly, it is less likely to develop resistance against this new agent, and this will be a major advantage over current antibiotics, for which bacteria had already become resistant.
“TB is an amazingly difficult disease to treat so we feel this is a significant breakthrough.
”The next stage of our research is to optimise further the chemical compound, but we hope clinical trials are up to four years away.”
Learn more: Scientists develop new drug treatment for TB
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- Tackling TB: A new trial is asking how to take tuberculosis tests to the peopleon April 29, 2021 at 3:32 pm
Roughly two in five people newly ill with TB worldwide are never diagnosed. In South Africa, this amounts to about 120,000 to 160,000 people per year. Now, a new study called XACT III is testing ways ...
- The tuberculosis pathogen releases its toxin via a novel protein transport systemon April 29, 2021 at 8:38 am
Six years ago, scientist Michael Niederweis described the first toxin ever found for the deadly pathogen Mycobacterium tuberculosis. The toxin, tuberculosis necrotizing toxin or TNT, became the ...
- Patralekhaa recalls battling tuberculosis at teenage as she pens a gratitude letter for her late fatheron April 29, 2021 at 3:02 am
Actor Patralekhaa who recently lost her father Ajit Paul, took to her social media handles to share a long letter to her late father which has been pe ...
- Tuberculosis Diagnostics Market Research Report by Test Type, by Type, by End_User - Global Forecast to 2025 - Cumulative Impact of COVID-19on April 29, 2021 at 2:22 am
This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Tuberculosis Diagnostics Market is expected to grow from USD 2,591.77 Million in ...
- Dr. Marty Makary: ‘More People Have Tuberculosis Than Coronavirus Right Now in the United States’on April 28, 2021 at 7:53 am
Dr. Marty Makary, Johns Hopkins University professor of public health, said Wednesday that there are more people with tuberculosis right now in the United States than those with COVID-19.
- Global Tuberculosis (TB) Diagnostics 2021 Market Report - Featuring Abbott, Bio-Rad and Cepheid Among Others - ResearchAndMarkets.comon April 28, 2021 at 2:53 am
Featuring Abbott, Bio-Rad and Cepheid Among Others - ResearchAndMarkets.com The “2021 Global Tuberculosis (TB) Diagnostics Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative ...
- Pulmonary Tuberculosis Identified as Possible Risk Factor for COPDon April 20, 2021 at 7:32 am
Investigators concluded that patients with prior pulmonary tuberculosis had an increased risk and high prevalence of chronic obstructive pulmonary disease (COPD), regardless of smoking history.
- New WHO handbook on systematic screening for active tuberculosison April 20, 2021 at 6:04 am
New World Health Organization (WHO) guidelines and handbook on systematic screening for active tuberculosis were published in March 2021. The handbook cites two studies from Ph.D. students Olivia ...
- Tuberculosis Drugs Market Size, Share, Growth,Trends, COVID-19 Analysis and Forecast 2021-2028on April 19, 2021 at 9:57 pm
The Global Tuberculosis Drugs market research report provides 360-degree information about the respective market with the primary focus on the market definition, drivers, opportunities, restraints, ...
via Bing News